P737: The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable resultsECCO '18 Vienna
2018
P738: Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remittersECCO '18 Vienna
2018
P739: Early use of anti-TNF in Crohn’s disease is associated with higher rate of biological and endoscopic remissionECCO '18 Vienna
2018
P740: Efficacy and safety of vedolizumab in inflammatory bowel disease: Real-life experienceECCO '18 Vienna
2018
P741: Very high rate of tuberculosis complicating infliximab therapy for inflammatory bowel disease despite tuberculosis screening in IndiaECCO '18 Vienna
2018
P742: Long-term outcome of patients with ulcerative colitis and first course of intravenous corticosteroidsECCO '18 Vienna
2018
P743: Ustekinumab use in Crohn´s Disease: Does short-term effectiveness correlate to induction regimen?ECCO '18 Vienna
2018
P744: Therapeutic gain of continued, long-term infliximab therapy in Crohn’s disease patients with response but non-remission after one year of infliximab therapyECCO '18 Vienna
2018
P745: Switching between anti-TNF originator and biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic reviewECCO '18 Vienna
2018
P746: Anthropometric measures in adolescents with inflammatory bowel disease: A population-based studyECCO '18 Vienna
2018
P748: Clinical outcomes and prognostic factors of methotrexate therapy in combination with anti-TNF agents in inflammatory bowel diseaseECCO '18 Vienna
2018
P749: A comparative analysis of low bioavailability steroids in inducing clinical response and remission in ulcerative colitis: Budesonide MMX as the safest optionECCO '18 Vienna
2018
P750: Predictors of quick remission after cyclosporine A therapy in Paediatric ulcerative colitisECCO '18 Vienna
2018
P751: Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapyECCO '18 Vienna
2018
P752: Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomised trialECCO '18 Vienna
2018
P753: Vedolizumab trough levels during induction in IBD patients: A longitudinal observational retrospective studyECCO '18 Vienna
2018